HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Santos, Lívia O ^a   Marinho, Fernanda A ^b   Altoé, Ellen F ^a   Vitório, Bianca S ^a   Alves, Carlos R ^a   Britto, Constança ^a   Motta, Maria Cristina M ^b   Branquinha, Marta H ^b   Santos, André L S ^b   d'Avila Levy, Claudia M ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; CYSTEINE PEPTIDASE B; GLYCOPROTEIN GP 63; INDINAVIR; LOPINAVIR; NELFINAVIR; PEPSTATIN; PEPTIDASE; SAQUINAVIR; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; PROTEINASE INHIBITOR; PYRIMIDINONE DERIVATIVE;

AMASTIGOTE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL ULTRASTRUCTURE; CHROMATIN CONDENSATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENDOPLASMIC RETICULUM; FEMALE; HOST PARASITE INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROLYSIS; LEISHMANIA; LEISHMANIASIS; MIXED INFECTION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROMASTIGOTE; AIDS RELATED COMPLEX; ANIMAL; CYTOLOGY; DRUG EFFECT; HUMAN; LEISHMANIA MEXICANA; MACROPHAGE; PARASITOLOGY; PATHOGENICITY; ULTRASTRUCTURE;

HUMAN IMMUNODEFICIENCY VIRUS 1; LEISHMANIA AMAZONENSIS; PROTOZOA;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; HIV PROTEASE INHIBITORS; HUMANS; LEISHMANIA MEXICANA; MACROPHAGES; NELFINAVIR; PROTEASE INHIBITORS; PYRIMIDINONES;

EID: 63449107184     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004918     Document Type: Article

References (56)

1. World Health Organization (2007) Report of the Fifth Consultative Meeting on Leishmania/HIV Co-infection. WHO, p. 1-38. Addis Ababa, Ethiopia: World Health Organization.
2. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, et al. (2008) The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334-359.
3. Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC (2008) Mucosal leishmaniasis. Current scenario and prospects for treatment. Acta Trop 105: 1-9.
4. Powderly WG, Landay A, Lederman MM (1998) Recovery of the immune system with antiretroviral therapy. The end of opportunism? JAMA 280: 72-77.
5. Mastroianni CM, Lichtner M, Mengoni F, D'Agostino C, Forcina G, et al. (1999) Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1 infected patients. AIDS 13: 883-890.
6. Mezzaroma I, Carlesimo M, Pinter E, Alario C, Sacco G, et al. (1999) Long-term evaluation of T-cell subsets and Tcell function after HAART in advanced stage HIV-1 disease. AIDS 13: 1187-1193.
7. Malhotra U, Berrei MM, Huang Y, Maree J, Brown DJ, et al. (2000) Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis 181: 121-131.
8. Desjeux P, Alvar J (2003) Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 97: 3-15.
9. Pozio E, Morales MA (2005) The impact of HIV-protease inhibitors on opportunistic parasites. Trends Parasitol 21: 58-63.
10. Blasi E, Colombari B, Orsi CF, Pinti M, Troiano L, et al. (2004) The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Cryptococcus neoformans. FEMS Immunol Med Microbiol 42: 187-195.
11. Bektic J, Lell CP, Fuchs A, Stoiber H, Speth C, et al. (2001) HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. FEMS Immunol Med Microbiol 31: 65-71.
12. Palmeira VF, Kneipp LF, Rozental S, Alviano CS, Santos AL (2008) Beneficial effects of HIV aspartyl peptidase inhibitors on the human pathogen Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence. PLoS ONE 3: e3382.
13. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, et al. (2005) Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 49: 2983-2985.
14. Savoia D, Allice T, Tovo PA (2005) Antileishmanial activity of HIV protease inhibitors. Int J Antimicrob Agents 26: 92-94.
15. Alexander J, Satoskar AR, Russel DG (1999) Leishmania species: Models of intracellular parasitism. J Cell Sci 112: 2993-3002.
16. Mottram JC, Coombs GH, Alexander J (2004) Cysteine peptidases as virulence factors of Leishmania. Curr Opin Microbiol 7: 375-381.
17. Yao C, Donelson JE, Wilson ME (2003) The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function. Mol Biochem Parasitol 132: 1-16.
18. Vermelho AB, Giovanni-de-Simone S, d'Avila-Levy CM, Santos ALS, Melo ACN, et al. (2007) Trypanosomatids and peptidases: a target for drug development. Curr Enz Inhib 3: 19-48.
19. d'Avila-Levy CM, Marinho FA, Santos LO, Martins JL, Santos AL, et al. (2006) Antileishmanial activity of MDL 28170, a potent calpain inhibitor. Int J Antimicrob Agents 28: 138-142.
20. Dutta A, Bandyopadhyay S, Mandal C, Chatterjee M (2005) Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis. Parasitol Int 54: 119-122.
21. Pereira FM, Elias CGR, d'Avila-Levy CM, Branquinha MH, Santos ALS (2008) Cysteine peptidases in Herpetomonas samuelpessoai are modulated by temperature and dimethylsulfoxide-triggered differentiation. Parasitology 136: 45-54.
22. Soares RMA, Santos ALS, Bonaldo MC, Andrade AF, Alviano CS, et al. (2003) Leishmania (Leishmania) amazonensis: differential expression of proteinases and cell- surface polypeptides in avirulent and virulent promastigotes. Exp Parasitol 104: 104-112.
23. Alvar J, Canabate C, Gutierrez-Solar B, Jimenez M, Laguna F, et al. (1997) Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10: 298-319.
24. Cruz I, Nieto J, Moreno J, Canavate C, Desjeux P, et al. (2006) Leishmania/HIV co-infections in the second decade. Indian J Med Res 123: 357-388.
25. Lopez-Velez R, Perez-Molina JA, Guerrero A, Baquero F, Villarrubia J (1998) Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 58: 436-443.
26. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E (2001) Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80: 54-73.
27. Gradoni L, Scalone A, Gramiccia M, Troiani M (1996) Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy. AIDS 10: 785-791.
28. Andrews L, Friedland G (2000) Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy. Infect Dis Clin North Am 14: 901-928.
29. Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, et al. (2001) Sex differences in HAART-associated dyslipidaemia. AIDS 15: 725-734.
30. Saag MS, Schooly RT (1998) Antiretroviral chemotherapy. In: Remington J, Schwartz MN, eds. Current Clinical Topics in Infectious Disease. Boston: McGraw Hill Book Co. pp 154-179.
31. Marques N, Cabral S, Sá R, Coelho F, Oliveira J, et al. (2007) Visceral leishmaniasis and HIV infection in the HAART era. Acta Med Port 20: 291-298.
32. Ruchel R, Ritter B, Schaffrinski M (1990) Modulation of experimental systemic murine candidosis by intravenous pepstatin A. Zentralbl Bakteriol 273: 391-403.
33. Flexner C (1998) HIV-protease inhibitors. N Engl J Med 338: 1281-1292.
34. Cupolillo E, Aguiar Alves F, Brahim LRN, Naiff MF, Pereira LOR, et al. (2001) Recent advances in the taxonomy of the new world leishmanial parasites. Med Microbiol Immunol 190: 57-60.
35. Chang KP, Akman L, Nielsen JS (1999) Leishmania virulence and genetic heterogeneity. Clin Dermatol 17: 269-273.
36. Trudel N, Garg R, Messier N, Sundar S, Ouellette M, et al. (2008) Intracellular Survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. J Infect Dis 198: 1292-1299.
37. Alves CR, Corte-Real S, Bourguignon SC, Chaves CS, Saraiva EM (2005) Leishmania amazonensis: early proteinase activities during promastigote-amastigote differentiation in vitro. Exp Parasitol 109: 38-48.
38. Valdivieso E, Dagger F, Rascon A (2007) Leishmania mexicana: identification and characterization of an aspartyl proteinase activity. Exp Parasitol 116: 77-82.
39. Kissova I, Plamondon LT, Brisson L, Priault M, Renouf V, et al. (2006) Evaluation of the roles of apoptosis, autophagy, and mitophagy in the loss of plating efficiency induced by Bax expression in yeast. J Biol Chem 281: 36187-36197.
40. Dunn WA (1994) Autophagy and related mechanisms of lysosome-mediated protein degradation. Trends Cell Biol 4: 139-142.
41. Seglen PO, Bohley P (1992) Autophagy and other vacuolar protein degradation mechanisms. Experientia 48: 158-172.
42. Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6: 463-477.
43. Shintani T, Klionsky DJ (2004) Autophagy in health and disease: a double-edged sword. Science 306: 990-995.
44. Gonzalez-Polo RA, Boya P, Pauleau AL, Jalil A, Larochette N, et al. (2005) apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci 118: 3091-3102.
45. Monari C, Pericolini E, Bistoni G, Cenci E, Bistoni F, et al. (2005) Influence of indinavir on virulence and growth of Cryptococcus neoformans. J Infect Dis 191: 307-311.
46. Tiuman TS, Ueda-Nakamura T, Garcia Cortez DA, Dias Filho BP, Morgado-Diaz JA, et al. (2005) Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother 49: 176-182.
47. Williams RA, Tetley L, Mottram JC, Coombs GH (2006) Cysteine peptidases CPA and CPB are vital for autophagy and differentiation in Leishmania mexicana. Mol Microbiol 61: 655-674.
48. Pereira BA, Alves CR (2008) Immunological characteristics of experimental murine infection with Leishmania (Leishmania) amazonensis. Vet Parasitol 58: 239-255.
49. Robertson CD (1999) The Leishmania mexicana proteasome. Mol Biochem Parasitol 103: 49-60.
50. Rabello A, Orsini M, Disch J (2003) Leishmania/HIV co-infection in Brazil: an appraisal. Ann Trop Med Parasitol 97: 17-28.
51. Desjeux P, Alvar J (2003) Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 97: 3-15.
52. Barat C, Zhao C, Ouellette M, Tremblay MJ (2007) HIV-1 replication is stimulated by sodium stibogluconate, the therapeutic mainstay in the treatment of leishmaniasis. J Infect Dis 195: 236-245.
53. Zhao C, Papadopoulou B, Tremblay MJ (2004) Leishmania infantum enhances human immunodeficiency virus type-1 replication in primary human macrophages through a complex cytokine network. Clin Immunol 113: 81-88.
54. Zhao C, Thibault S, Messier N, Ouellette M, Papadopoulou B, et al. (2006) In primary human monocyte-derived macrophages exposed to Human immunodeficiency virus type 1, does the increased intracellular growth of Leishmania infantum rely on its enhanced uptake? J Gen Virol 87: 1295-1302.
55. Barreto-de-Souza V, Medeiros TX, Motta MCM, Chequer Bou-Habib D, Saraiva EM (2008) HIV-1 infection and HIV-1 Tat protein permit the survival and replication of a non-pathogenic trypanosomatid in macrophages through TGF-beta1 production. Microbes Infect 10: 642-649.
56. Garg R, Lodge R, Descoteaux A, Tremblay MJ (2008) Leishmania infantum promastigotes reduce entry of HIV-1 into macrophages through a lipophosphoglycan-mediated disruption of lipid rafts. J Infect Dis 197: 1701-1708.